pharmaphorum| News & views on pharma and biotech’s evolving future

Sales & Marketing

virtual electronic medical record interface

Sponsored

5 forces reshaping pharma commercialisation in 2026

As infrastructure bottlenecks ease and regulatory frameworks mature, pharma's AI adoption is shifting from proof-of-concept to production-grade deployment

Oncology

After 'Year of Harvest', Bayer looks to diversify modalities

Bayer Oncology's strategy has led to strong showings in small molecules and radiotherapies. Now they're on the hunt for ADCs, bispecifics, and more.

Market Access

EVERSANA leaders on digital-first models, affordability, and...

Patients

Psychiatrist with patient in talking session

Patient centricity in psychiatric management: Bipolar I

Discover what clinicians can do to foster more patient-centred psychiatric care in a Q&A with neuropsychiatric physician assistant Rebecca Barbee.

News

Arrows on grey background pointing left and right

FDA relents and will review Moderna's flu shot

The FDA will start a review of Moderna's flu jab mRNA-1010, after refusing to accept the filing last week, with a new "regulatory approach."

Featured Content

Oncology

After 'Year of Harvest', Bayer looks to diversify modalities

Bayer Oncology's strategy has led to strong showings in small molecules and radiotherapies. Now they're on the hunt for ADCs, bispecifics, and more.

Market Access

EVERSANA leaders on digital-first models, affordability, and...

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

R&D

JPM2026 wrap-up with Nicole Raleigh and Jonah Comstock

On JPM2026 and healthcare investment today, with Jonah Comst...

Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.

Patients

Interview at JPM26 with Alexander Schneider

New hope for ovarian cancer, with Alexander Schneider

Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.

Digital

Sponsored

Expert Directed Applied Intelligence: Redefining AI in Life ...

In a new white paper from Lumanity, explore why the most powerful AI will always be human-directed.

Newsletters and Deep Dive
digital magazine

Latest News

News

FDA relents and will review Moderna's flu shot

The FDA will start a review of Moderna's flu jab mRNA-1010, after refusing to accept the filing last week, with a new "regulatory approach."

News

FDA starts review of BMS's 'celmod' for multiple myeloma

Bristol Myers Squibb could be months away from bringing the first 'celmod' to market, as the FDA starts a review of iberdomide for multiple myeloma.

News

Number of UK biotech companies rising, says report

A report has found that the number of life sciences companies domiciled in the UK has grown by nearly a quarter in the last few years.

News

Novartis' oral BTK drug moves the needle in CINDU

Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.

Views & Analysis

Oncology

After 'Year of Harvest', Bayer looks to diversify modalities

Bayer Oncology's strategy has led to strong showings in small molecules and radiotherapies. Now they're on the hunt for ADCs, bispecifics, and more.

Patients

Patient centricity in psychiatric management: Bipolar I

Discover what clinicians can do to foster more patient-centred psychiatric care in a Q&A with neuropsychiatric physician assistant Rebecca Barbee.

R&D

Changing Faces: Board of Directors, January 2026

January was a relatively quiet month for Board news, but there were some notable moves here and there.

Sales & Marketing

Sponsored

5 forces reshaping pharma commercialisation in 2026

As infrastructure bottlenecks ease and regulatory frameworks mature, pharma's AI adoption is shifting from proof-of-concept to production-grade deployment